| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cassava Sciences, Inc.$2.38
+0.19 (+8.68%)
C 42Pipeline Score Overvalued Biotech · Clinical
Market Cap
114.97 M
EPS
-2.20
P/E Ratio
-
Value Trade
4.98 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
4.54 M
Operating CF
-8.88 M
Total Assets
108.37 M
Total Liabilities
40.23 M
Equity
68.14 M
5.31 %
Week
23.32 %
1 Month
-26.32 %
3 Month
12.8 %
6 Month
-95.44 %
5 Year
-97.65 %
All Time
Cash Data
Cash Position
86.57 M
Monthly Burn
2.96 M
Runway
26.5 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.09 M
52 Week Range
1.15 - 4.98
% held by Insiders
2.05 %
% held by Institutions
28.11 %
Enterprise Value
8.89 M
Total Shares
48.32 M
Short %
13.18 %
Float Shares
47.02 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | Simufilam | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-31 | Simufilam | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-31 | Simufilam | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C42
Pipeline Score $51M
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.4x
rNPV / MCap Top 63%
Micro Cap (rank 343 of 923)
Percentile RankCassava Sciences, Inc. carries a moderate pipeline score (42/100), with $1.0B risk-adjusted pipeline value, led by Simufilam in Alzheimer Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simufilam Small molecule | Alzheimer Disease | Phase 3 | NCT04079803 | 44% | $428M | COMPLETED | 1,088 | - | - | Mar 31, 2020 | - | Sep 29, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
simufilam | Alzheimer's disease | Phase 3 | 2026-01-13 | RETHINK ALZ: participants 804, reported November 2024; REFOCUS ALZ: participants 1125, reported March 2025; exploratory: 21% of participants (33 of 160) were unexpectedly amyloid negative at baseline Read More | Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease Read More | |
simufilam | Alzheimer's disease | Phase 3 | 2026-01-13 | RETHINK ALZ: participants 804, reported November 2024; REFOCUS ALZ: participants 1125, reported March 2025; exploratory: 21% of participants (33 of 160) were unexpectedly amyloid negative at baseline Read More | Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease Read More | |
simufilam | Alzheimer's disease | Phase 3 | 2026-01-13 | RETHINK ALZ: participants 804, reported November 2024; REFOCUS ALZ: participants 1125, reported March 2025; exploratory: 21% of participants (33 of 160) were unexpectedly amyloid negative at baseline Read More | Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SAVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SAVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SAVA ranks across every disease it competes inCompetitive Position is a premium feature
See how SAVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial